VDR Gene Vitamin D and Immune Function | Decoding Inflammation

By Alberto Rivera, MD · 2026-05-06 · 6 min read

Vitamin D as Genomic Signal

Once activated to its hormonal form, 1,25-dihydroxyvitamin D3, vitamin D does not simply support calcium absorption and bone density. It binds the vitamin D receptor (VDR), which then translocates to the nucleus and modulates transcription across an estimated 3 to 5 percent of the human genome. The immune implications are profound: VDR signaling suppresses Th1-driven inflammatory responses, promotes regulatory T cell differentiation, enhances innate antimicrobial peptide production, and reduces macrophage-mediated pro-inflammatory cytokine release.

The VDR gene encodes this receptor, and its polymorphisms determine how effectively the activated hormone signal is read. The most studied variants, BsmI (rs1544410), FokI (rs2228570), ApaI (rs7975232), and TaqI (rs731236), collectively modulate receptor expression levels, protein stability, and transcriptional activation efficiency.

The FokI Variant and Receptor Length

The FokI polymorphism is particularly consequential because it alters the translation start site of the VDR protein itself, producing a receptor that is either 427 or 424 amino acids in length. The shorter ff variant is more transcriptionally active. The longer FF variant requires more ligand to achieve equivalent transcriptional output, meaning FF carriers need higher circulating 25-OH vitamin D to drive the same immune-regulatory response.

A 2025 systematic review in Nutrients confirmed that FF homozygotes show attenuated VDR-mediated immune signaling at standard vitamin D serum levels, and require higher therapeutic targets, typically above 60 ng/mL, to achieve the same anti-inflammatory effect observed in ff carriers at 40 ng/mL. Dosing vitamin D without knowing VDR genotype is equivalent to writing a drug prescription without knowing pharmacogenomics.

The CYP27B1 and CYP24A1 Context

VDR variants do not operate in isolation. CYP27B1 encodes the enzyme that activates vitamin D to its hormonal form, and CYP24A1 encodes the enzyme that degrades it. Polymorphisms in both genes further modulate the effective hormonal signal delivered to VDR. A CYP24A1 high-activity variant combined with a low-sensitivity VDR genotype creates compounding insufficiency.

The GENEFLAMMATION protocol maps all three layers, synthesis, receptor sensitivity, and degradation, to build a vitamin D genomic profile that defines both the therapeutic serum target and the supplementation dose required to achieve it for each patient's specific genomic architecture.